Compare iShares MSCI ACWI ETF (ACWI) vs BioNTech SE - ADR (BNTX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
iShares MSCI ACWI ETF vs BioNTech SE - ADR — how do they compare? iShares MSCI ACWI ETF trades at $155.57, while BioNTech SE - ADR trades at $93 (market cap $23.84B). The key difference: iShares MSCI ACWI ETF is trading nearer its 52-week high, BioNTech SE - ADR nearer its low. Which is the better fit depends on your goals.
| ACWI | BNTX | |
|---|---|---|
52-Week High | $159.97 | $119.34 |
52-Week Low | $128.32 | $83.89 |
Market Cap | — | $23.84B |
Sector | — | Health |
Enterprise Value | — | $7.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACWI trades at $157.97, up 1.17% with a bullish technical signal from moving averages. The ETF shows strong institutional interest and positive news flow, with a dividend scheduled for June 2026. Key support lies at $156, while resistance is at $159.
Outlook remains positive due to robust EPS growth and investor inflows into global equity ETFs. Risks include overbought technical conditions and market volatility. The stock's valuation and momentum support a constructive view for long-term investors.
BioNTech (BNTX) trades at $94.29, down 3.34% on the day, as the company navigates its transition from COVID-19 vaccine dominance to oncology focus. The stock shows a bullish technical signal with strong analyst support (87.5% buy ratings) and a $130.83 consensus price target. However, fundamental challenges persist with negative net income margins (-44.64%) and declining revenues from pandemic peak levels, offset by a robust $16.78 billion cash position and ongoing $1 billion share repurchase program.
The outlook balances promising oncology pipeline developments against near-term profitability challenges. Investment opportunity lies in BioNTech's cash-rich balance sheet and advancing cancer therapeutics, while risks include execution uncertainty in the therapeutic transition, manufacturing restructuring costs, and competitive pressure in the oncology space. The stock presents a high-risk, high-reward proposition for investors betting on successful pipeline execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI ACWI ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index is a free float-adjusted market capitalization index designed to measure the combined equity market performance of developed and emerging markets countries.
Read more on ACWI →About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →
